Cellular immune responses in multiple sclerosis patients treated with interferon-beta

Clin Exp Immunol. 2013 Mar;171(3):243-6. doi: 10.1111/cei.12016.

Abstract

We investigated cellular immune responses at baseline in peripheral blood mononuclear cells (PBMC) of patients with multiple sclerosis (MS) treated with interferon (IFN)-β and classified into responders and non-responders according to clinical response criteria. Levels for IFN-γ, interleukin (IL)-17A, IL-17F, IL-10 and IL-4 were determined in activated PBMC of 10 responders, 10 non-responders and 10 healthy controls by cytometric bead arrays. Cytokine levels in cell culture supernatants were similar between responders and non-responders, and comparable to those obtained in healthy controls. These findings do not support differential cellular immune responses in PBMC at baseline between IFN-β responders and non-responders.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Cytokines / analysis
  • Female
  • Humans
  • Interferon-beta / immunology
  • Interferon-beta / therapeutic use*
  • Male
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*

Substances

  • Cytokines
  • Interferon-beta